Losartan Potassium Tablet, Film Coated
Product Images NDC 50090-7946

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-7946). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907946)

This text provides storage instruction for "Losaaran" tablets, advising to store them at 8.7 degrees Celsius. The package contains 90 tablets.*

FDA Label Image

Losartanpotassiumfigure1 (Losartanpotassiumfigure1)

This text mentions the comparison between Atenolol and Losartan potassium in terms of the primary endpoint for patients. It indicates an adjusted risk reduction of 13% with a p-value of 0.021. The study appears to be conducted over a period of 66 months, with data points at intervals of 6 months.*

FDA Label Image

Losartanpotassiumfigure2 (Losartanpotassiumfigure2)

This text appears to be a table showing the percentage of patients with fatal/non-fatal stroke over a period of 66 study months for two different medications, Atenolol and Losartan potassium. It provides insights into the impact of these medications on stroke occurrence.*

FDA Label Image

Losartanpotassiumfigure3 (Losartanpotassiumfigure3)

The text provides results of a study comparing the effects of Losartan Potassium and Atenolol on various parameters including stroke, in patients under 65 and over 65 years of age with female gender, diabetes, and history of cardiovascular disease. The data includes event rates, hazard ratios, and number of patients in different subgroups. The study suggests a comparison of the two medications in terms of their effectiveness and safety profiles.*

FDA Label Image

Losartanpotassiumfigure4 (Losartanpotassiumfigure4)

This text provides information on the percentage of patients with an event in two groups, one with Losartan Potassium and the other with Placebo. The risk reduction between the two groups is noted as 16.1%, with a statistical significance of p=0.022.*

FDA Label Image

Losartanpotassiumstructure (Losartanpotassiumstructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.